Related references
Note: Only part of the references are listed.A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update
Andrea Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Pituitary-Tumor Endocrinopathies
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider
Eliza B. Geer et al.
PITUITARY (2020)
An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies
Maria Fleseriu et al.
PITUITARY (2020)
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Monica R. Gadelha et al.
ENDOCRINE REVIEWS (2019)
Acromegaly
Annamaria Colao et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review
Michiel J. van Esdonk et al.
PITUITARY (2018)
A Consensus Statement on acromegaly therapeutic outcomes
Shlomo Melmed et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Acromegaly: a challenging condition to diagnose
Salma AlDallal
INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2018)
Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications
Ching-Jen Chen et al.
ACTA NEUROCHIRURGICA (2017)
Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly
Christian J. Strasburger et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
Sebastian J. C. M. M. Neggers et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial
Shlomo Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
Michael Sheppard et al.
PITUITARY (2015)
Reference Intervals for Insulin-like Growth Factor-1 (IGF-I) From Birth to Senescence: Results From a Multicenter Study Using a New Automated Chemiluminescence IGF-I Immunoassay Conforming to Recent International Recommendations
Martin Bidlingmaier et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
John D. Carmichael et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly: An Endocrine Society Clinical Practice Guideline
Laurence Katznelson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
A. Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
EXPERT CONSENSUS DOCUMENT A consensus on the medical treatment of acromegaly
Andrea Giustina et al.
NATURE REVIEWS ENDOCRINOLOGY (2014)
A Novel Suspension Formulation Enhances Intestinal Absorption of Macromolecules Via Transient and Reversible Transport Mechanisms
Shmuel Tuvia et al.
PHARMACEUTICAL RESEARCH (2014)
Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial
Lucio Vilar et al.
ENDOCRINE (2014)
Efficacy and Safety of an Octreotide Implant in the Treatment of Patients With Acromegaly
Carla Chieffo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Automated 22-kD Growth Hormone-Specific Assay without Interference from Pegyisomant
Jenny Manolopoulou et al.
CLINICAL CHEMISTRY (2012)
Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?
Claudia Ramirez et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Oral Octreotide Absorption in Human Subjects: Comparable Pharmacokinetics to Parenteral Octreotide and Effective Growth Hormone Suppression
S. Tuvia et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
Yasemin Tutuncu et al.
PITUITARY (2012)
Surgery and Radiosurgery for Acromegaly: A Review of Indications, Operative Techniques, Outcomes, and Complications
Yvette Marquez et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2012)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND TREATMENT OF ACROMEGALY-2011 UPDATE: EXECUTIVE SUMMARY
Laurence Katznelson et al.
ENDOCRINE PRACTICE (2011)
A Consensus on Criteria for Cure of Acromegaly
A. Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly
Roberto Salvatori et al.
PITUITARY (2010)
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide AutogelA® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
Shlomo Melmed et al.
PITUITARY (2010)
Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?
Pamela U. Freda
CLINICAL ENDOCRINOLOGY (2009)
Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly
Philippe Chanson et al.
CLINICAL ENDOCRINOLOGY (2008)
Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective
J. S. Bevan et al.
CLINICAL ENDOCRINOLOGY (2008)
Variability and reliability of single serum IGF-I measurements: Impact on determining predictability of risk ratios in disease development
D Milani et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Share Paper
